Product Description
ZG006 is a trispecific antibody against CD3 and two different DLL3 epitopes. The anti-DLL3 end of ZG006 binds to different DLL3 epitopes on the surface of tumor cells, and the anti-CD3 end binds to T cells. ZG006 engages tumor cells and T cells, draws T cells closer to tumor cells, and uses T cells to specifically kill tumor cells. The results of preclinical studies show that ZG006 has a significant tumor inhibitory effect on mouse tumor models, and can cause a significant proportion of mouse tumors to completely regress, indicating that ZG006 has a strong tumor killing effect. ZG006 has shown a good safety profile with low toxic side effects in non-human primates. (Sourced from: https://www.zelgen.com/xinwenzhongxin/2023/07-31/345.html)
Mechanisms of Action: DLL3 Inhibitor,CD3 Inhibitor
Novel Mechanism: No
Modality: Trispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Suzhou Zelgen
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Neuroendocrine Carcinoma|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ZG006US001 | P1 |
Not yet recruiting |
Small Cell Lung Cancer |
2026-12-01 |
|
| ZG006-003 | P2 |
Recruiting |
Neuroendocrine Carcinoma|Small Cell Lung Cancer |
2026-05-01 |
|
| ZG006-002 | P2 |
Recruiting |
Neuroendocrine Carcinoma|Small Cell Lung Cancer |
2026-04-01 |
|
| ZG006-001 | P2 |
Recruiting |
Neuroendocrine Carcinoma|Small Cell Lung Cancer |
2025-09-01 |